• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173500 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
3 a! A* c! S$ w% X, a5 B5 G
/ E" j8 d- c; s, _8 @$ p
* h4 G: |* V" Y/ B: X7 _' MSub-category:
. F" I% ?( K, ^8 I7 E" ^Molecular Targets
% x& l& q* a' ?, x6 b* s
; B1 t/ ]; c: L8 a9 g. P/ `7 t0 I& V2 N+ N! p, D/ ~! L4 Y
Category:
% u9 H3 s& J+ o/ C2 u% ]Tumor Biology
# w0 R: y  \2 |6 q7 M3 N/ s* k/ K6 Z/ ?, h9 n

3 S& d0 s$ q; x9 x3 h. f, ^Meeting:  N- R! M- c# o- y* y. o9 J
2011 ASCO Annual Meeting 1 S) b! ~. Q! J1 l0 n. t3 `. y
5 e4 K' O* |+ ?' e8 ]7 O

9 Y9 T8 [4 G& O  _Session Type and Session Title:
, u9 o2 e8 \$ O$ GPoster Discussion Session, Tumor Biology * L5 c( e9 O; G. j
1 P* K1 x$ T- B6 ?

% q# S+ r; P( `/ @3 @" W  GAbstract No:
) g) O9 @2 V3 x) i1 O7 @( J* Y4 w2 N10517 , X6 v, C1 \; A+ q8 Y3 r& E
* ^3 m: A/ f2 u9 f
5 ]9 b7 g$ B4 j2 D& S
Citation:3 f  m$ @/ s# _" M* j0 j5 }
J Clin Oncol 29: 2011 (suppl; abstr 10517)
, v3 _) y6 ?* f; E3 n
; h# l: b1 s% e/ U6 h8 R, i( g( F5 j& \  l  s9 E0 c
Author(s):
! s' w6 J& I  T# W- k( B2 HJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
% q# r4 q4 ?# b3 X4 C+ K; C# j6 G4 L' C# {. G
, U; A; u( j2 D/ u/ \

: M) F6 {" ?) E+ a9 ~9 gAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
% a; w" a+ `- P2 X$ l* {% M* z. i. t; M% o* X" N
Abstract Disclosures3 \( u# b6 p6 I' ]8 M7 X
- [( d3 ]; i6 n  h  `; B% |  n
Abstract:. s2 I2 H6 h$ s  j
4 N! H# n; A" ^- N& h4 m8 d
% a) j1 q8 O# H9 {
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- g( x. ]* y4 I. \  E- L

4 W- }. Z& u4 `5 r / k* r7 K8 G8 I  p" m* K1 T! x8 |# d
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ( e( t, X8 Y( N2 D* J% q/ j, o
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
2 q, n, c: j; [1 J7 n# k5 D
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 , ^1 A0 i; f6 a& T& r1 k# q
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
3 R+ X% S/ k+ h% W6 I! ^+ CALK一个指标医院要900多 ...
% E, d' T$ p2 M% f2 E
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
9 m! F" N3 E4 `$ Q' r$ D6 |6 p7 g- T' y/ \) n" _) O* a' P  a4 L% K6 {# e
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表